Leukemia treatment may erase vaccine protection—study tests if re-vaccination works
NCT ID NCT07422337
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether children and young adults (up to age 21) treated for B-cell acute lymphoblastic leukemia with the immunotherapy drug blinatumomab still have protection from routine childhood vaccines. Researchers will measure antibody levels for diseases like tetanus, hepatitis B, and measles. If protection is low, they will see if re-vaccination can restore it. The goal is to create a clear vaccination plan for these patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arkansas Children's
RECRUITINGLittle Rock, Arkansas, 72202, United States
-
Arkansas Children's Northwest
RECRUITINGSpringdale, Arkansas, 72762, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells outsmart resistant blood cancers?
- Can donor immune cells be engineered to fight blood cancer?
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Can a Chemo-Antibody combo beat a tough leukemia?
- Personalized chemo dosing may boost leukemia remission in kids
- Can targeted drugs blinatumomab and venetoclax improve outcomes for childhood leukemia?